Selinexor + Elotuzumab + Pomalidomide + Dexamethasone Oral

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Apr 19, 2022 โ†’ Mar 1, 2029

About Selinexor + Elotuzumab + Pomalidomide + Dexamethasone Oral

Selinexor + Elotuzumab + Pomalidomide + Dexamethasone Oral is a phase 3 stage product being developed by Karyopharm Therapeutics for Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT05028348. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05028348Phase 3Active